View DividendDuChemBIOLtd マネジメントマネジメント 基準チェック /04現在、CEO に関する十分な情報がありません。主要情報 最高経営責任者n/a報酬総額CEO給与比率n/aCEO在任期間no dataCEOの所有権n/a経営陣の平均在職期間データなし取締役会の平均在任期間データなし経営陣の近況Less than half of directors are independent Nov 16Less than half of directors are independent Apr 27DuChemBIO Co.,Ltd., Annual General Meeting, Mar 29, 2021Mar 06すべての更新を表示Recent updatesDuChemBIO Co.,Ltd. has filed a Follow-on Equity Offering.Aug 27Less than half of directors are independent Nov 16Less than half of directors are independent Apr 27DuChemBIO Co.,Ltd., Annual General Meeting, Mar 29, 2021Mar 06Telix Pharmaceuticals Limited Enters into A Commercialisation and Partnership Agreement with Duchembio Co, LtdDec 03CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. (XKON:A176750) from Kim Jong-woo and others in a reverse merger transaction.Nov 26New 90-day high: ₩10,300 Nov 05DuChemBIO Co.,Ltd. announced that it has received KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.Sep 30+ 1 more updateNew 90-day high: ₩9,560 Sep 18New 90-day high - ₩7,300 Sep 03CEO（最高経営責任者DuChemBIOLtd CEOがいない、あるいは彼らに関するデータがない。View Ownership
Telix Pharmaceuticals Limited Enters into A Commercialisation and Partnership Agreement with Duchembio Co, LtdDec 03
CareCamp Inc. agreed to acquire DuChemBIO Co.,Ltd. (XKON:A176750) from Kim Jong-woo and others in a reverse merger transaction.Nov 26
DuChemBIO Co.,Ltd. announced that it has received KRW 4.5 billion in funding from RNR Partners Group Co., Ltd., YNK Company Inc.Sep 30+ 1 more update